DOCSLIB.ORG

Qualifying Therapeutic Discovery Project Grants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Qualifying Therapeutic Discovery Project Grants Qualifying Therapeutic Discovery Project Grants The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant. The project descriptions below were extracted from the applicant certification forms as submitted. Alabama $3,708,304.65 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Heparan Sulfate Agenta Biotechnologies Delivery in Barrier Membranes $59,614.76 $184,864.48 Inc and Soft Tissue Wound Closure DELIVERY OF GROWTH- AGENTA FACTOR CO-RECEPTOR BIOTECHNOLOGIES HEPARAN SULFATE IN $169,808.39 $6,666.50 INC BONE GRAFT SUBSTITUTES FOR REPAIR BioCryst BCX4208 for Treatment of $244,479.25 Pharmaceuticals Inc Gout BioCryst Peramivir for Treatment of $244,479.25 Pharmaceuticals, Inc Influenza BioCryst Forodesine for Treatment of $244,479.25 Pharmaceuticals, Inc CLL and CTCL BioCryst BCX4161 for Treatment of $86,380.89 Pharmaceuticals, Inc. Hereditary Angioedema JAK Inhibitors for Treatment BioCryst of Psoriasis, Ankylosing $244,479.25 Pharmceuticals, Inc. Spondylitis, & Multiple Sclerosis Disease Diagnostic Panel Diatherix Laboratories, Development Utilizing the $244,479.25 Inc. TEM-PCR Method Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EGEN-001 in Platinum- EGEN INC $244,479.25 Resistant Ovarian Cancer EGEN, INC. EGEN TheraSilence $244,479.25 Development of an Apparatus iCubate, Inc $244,479.25 for Performing am-PCR Phase 1, Open-label Syudy Evaluting the Safety of PNP Therapeutics Inc $244,479.25 Escalating Doses of Ad/PNP- F-araAMP SER-201 for the treatment of Serina Therapeutics, Inc $244,479.25 colorectal and ovarian cancer Development of an Vaxin Inc. Adenovirus-Vectored Nasal $244,479.25 Anthrax Vaccine Replication-Defective Adenovirus-Vectored Vaxin Inc. $161,175.00 $83,304.25 Influenza Vaccine Development Nanotechnology Enabled Vista Engineering Inc Temporomandibular Joint $29,059.63 $32,059.00 (TMJ) Prosthesis Development of sorptive nasal Volatile Analysis stent for diagnostic biomarker $23,600.00 $182,500.00 Corporation detection Arizona $7,503,090.80 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 AmpliMed Development of small-molecule $244,479.24 Corporation anti-cancer drugs NeuVax-adjuvant treatment for Apthera, Inc. $244,479.25 node positive breast cancer with Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 low to intermediate HER2 Development of Ultrasound Ardent Sound Inc. Therapy Device for Sebaceous $244,479.25 and Sweat Gland Treatment Ascalon IV Fenretinide $106,406.50 $138,072.74 International Inc Integrated platform for bioVidria, Inc. $47,799.50 $114,302.50 glycoform biomarker discovery TGEN COLLABORATION: BLUE HORSE GENETIC RISK FACTORS $179,589.50 $8,301.50 LABS, INC. FOR ALZHEIMER'S DISEASE (PHASE II) Oxidative stress markers in Blue Horse Labs, multiple matrices as biomarkers $7,160.00 $88,697.00 Inc. for disease Hematopoietic Stem Cell Therapy for HIV/AIDS Usifng Calimmune, Inc. $244,479.25 RNAi to Reduce Expression of CCR5 Cancer Prevention Eflornithine $189,893.77 $54,585.48 Pharmaceuticals Inc Capstone AZX100 for Idiopathic $78,150.00 $166,329.24 Therapeutics Corp Pulmonary Fibrosis (IPF) Cold Plasma Harmonic Cold Plasma medical Medical Technology for the Repair of $244,479.25 Technologies Living Cells, Tissue and organs. Eye Care and Cure Extra-Ocular Motility Monitor $63,720.71 Corporation (EOMM) Eye Care and Cure I-CORE $53,221.15 Corporation Gary A Flynn Multi-targeted Kinase Inhibitors PhD/Spacefill as Imaging and Therapeutic $27,000.00 Enterprises LLC Agents High Throughout qNPA miRNA Development $41,483.00 $5,419.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Genomics, Inc. Project High Throughput Mid Density Platform $73,830.00 $79,962.00 Genomics, Inc Development Project High Throughput qBead Development Project $67,940.00 $38,392.00 Genomics, Inc High Throughput Fusin Gene-SNV Mutation Tests $26,268.50 $28,273.50 Genomics, Inc Development Project High Throughput Pathogen Assay Development $11,131.00 $23,394.00 Genomics, Inc Project High Throughput DLBCL & Cell of Orgin $16,408.50 $8,707.00 Genomics, Inc Development Project High Throughput qSelect Assay Archive $16,026.50 $41,378.50 Genomics, Inc Development Project High Throughput qNPA Platform Technology $71,709.50 $117,348.00 Genomics, Inc Development Project High Throughput Melanoma Screening $20,359.50 Genomics, Inc Development Project High Throughput Radiation Exposure Monitoring $13,797.00 $2,081.00 Genomics, Inc Assay Development Project Hope Medical Treatment of Acute Myocardial $17,542.28 Enterprises, Inc Infarction Hope Medical Treatment of Sickle Cell Disease $3,250.00 $36,907.86 Enterprises, Inc. Recombinant fibrogen & HumaGene Inc $17,985.00 $14,500.00 thrombin InNexus DXL 625 $116,760.00 Biotechnology, Inc. INSYS Therapeutics, Fentanyl Sublingual Spray $244,479.24 Inc INSYS Therapeutics, Dronabinol Oral Solution $244,479.25 Inc Kinetic Muscles Inc Neuro Telerehabilitation System $221,667.65 $22,811.59 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Utilizing the MedApps System MedApps, Inc for Remotely Monitoring $244,479.24 Clinical Drug Therapies MSDx Multiple Biomarkers for Monitoring Sclerosis Multiple Sclerosis Patients - A $82,908.19 $47,063.66 Diagnostics, LLC Window into the Brain Biomarkers for Monitoring MSDx, Inc Multiple Sclerosis Patients - A $74,700.00 window into the Brain Development of molecular PathoGene, LLC assays for the identification and $37,850.50 resistance profiling of MRSA. Engineered Small-Diameter Protein Genomics Artery Grafts Using Synthesized $120,342.50 $124,136.75 Human Elastin Fibrinogen and fibrin Provista Life degradation product lung cancer $137,175.27 Sciences, LLC assay Provista Life Multivariate Breast Cancer $221,153.46 Sciences, LLC Detection and Screening Assay Provista Life Epigenetic Test for Alzheimer's $244,479.25 Sciences, LLC Disease Provista Life Lymphocyte Proliferation Test $180,664.68 Sciences, LLC for Early Alzheimer's Detection Prugen IP Holdings Drug Bioavailability $244,479.25 Inc Enhancement Delivery System Stabilized Chlorine Dioxide for Rowpar Treatment & Prevention of Oral $1,402.50 $3,673.00 Pharmaceuticals, Inc Candidiasis 0.5% Stabilized Chlorine Rowpar Dioxide for the Treatment and $2,881.00 $20,782.50 Pharmaceuticals, Inc Prevention for Gingivitis SALUTARIS SMD-A $244,479.24 MEDICAL Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 DEVICES, INC. Non-invasive boold glucose Sensys Medical Inc monitor for the diagnosis & $244,479.24 treatment of diabetes Southwest Scientific Dietary supplements enhanced Editing & for biofavanoids and antioxidants $2,850.00 $26,200.00 Consulting, LLC to treat human disease Susavion Discovery of Immunotherapeutic $85,997.50 $117,631.00 Biosciences, Inc Drugs Against Viral Infections Kit for noninvasive early Synbuild LLC $11,157.12 detection of pancreatic cancer SYNCARDIA COMPANION 2 DRIVER $54,080.75 SYSTEMS, INC Inline acuator for pMDI Thayer Medical medication delivery in ventilator $66,050.50 $112,333.50 Corporation circuits with 15 mm connection. Pre-Clinical and Clinical Transmed Oncology Development of DNMT1 $70,784.50 Inc inhibiting Compounds Valley Fever Late Stage Valley Fever - Phase $244,479.25 Solutions, Inc. II The Use of Bioelectric Wound Vomaris Care Devices for Improving $244,479.25 Innovations, Inc Healthcare Arkansas $730,294.80 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Mucosal and Cell Targeted RTB BioStrategies, Delivery of Novel Plant Produced $118,994.00 $125,485.25 LC Protein Therapeutics Pacific Vet Pre-clinical Trials for Unique $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Group - USA Competitive Exclusion Treatment Inc. for Gastrointestinal Disease New Biomarker Assays for Stage I Monitoring and Diagnosis of $171,756.22 $69,580.08 Diagnostics, Inc. Ovarian Cancer California $276,141,790.10 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 3-V BROAD SPECTRUM HOST BIOSCIENCES FACTOR DIRECTED $244,479.24 INC ANTIVIRAL THERAPEUTIC Application of continous negative 5iSciences, Inc. external pressure (cNEP) to the $22,834.35 $141,124.00 upper airway APF530- Prevention of A.P. Pharma, Inc Chemotherapy-induced Nausea $244,479.25 and Vomiting Aaken Guided Electrical Stimulation $49,026.40 $36,267.00 Laboratories Aardvark Nasal Irrigation/Aspiration $244,479.24 Medical, Inc. System Ablation Rapid and Simple Cure for Atrial $500.00 $243,979.25 Numerics Inc Fibrillation Acadia Pharmaceuticals Pimavanserin $244,479.25 Inc. Acaduceus Developing Novel Platinum Pharmaceutics based Targeted-Nanoparticles for $12,400.00 $132,500.00 Inc Anti-Cancer Drugs Acaduceus Developing Targeted Probe for $56,150.00 $180,000.00 Pharmeceutics PET imaging of Primary and Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Metastatic Melanoma Acceleration of Bone Fracture Accelalox Inc. $54,062.50 $132,430.00 Healing Access Scientific The Wand $244,479.25 Inc Gravitas: Gauging Responsiveness With a Accumetrics, Inc $244,479.25 VerifyNow Assay-impact on Thrombosis & Safety Development of and cancer ACEA treatment with Bis(4- $244,479.25 Biosciences Inc. fluorobenzyl)trisulfide (BFBTS) AcelRx Sufentanil NanoTab ™ Patient Pharmaceuticals, Controlled Anagesia (PCA) $244,479.25 Inc System AcelRx Pharmaceuticals, Triazolam/Sufentanil NanoTab ™ $244,479.24
Load more

Recommended publications
  • Evolutionary Origins of DNA Repair Pathways: Role of Oxygen Catastrophe in the Emergence of DNA Glycosylases
    cells Review Evolutionary Origins of DNA Repair Pathways: Role of Oxygen Catastrophe in the Emergence of DNA Glycosylases Paulina Prorok 1 , Inga R. Grin 2,3, Bakhyt T. Matkarimov 4, Alexander A. Ishchenko 5 , Jacques Laval 5, Dmitry O. Zharkov 2,3,* and Murat Saparbaev 5,* 1 Department of Biology, Technical University of Darmstadt, 64287 Darmstadt, Germany; [email protected] 2 SB RAS Institute of Chemical Biology and Fundamental Medicine, 8 Lavrentieva Ave., 630090 Novosibirsk, Russia; [email protected] 3 Center for Advanced Biomedical Research, Department of Natural Sciences, Novosibirsk State University, 2 Pirogova St., 630090 Novosibirsk, Russia 4 National Laboratory Astana, Nazarbayev University, Nur-Sultan 010000, Kazakhstan; [email protected] 5 Groupe «Mechanisms of DNA Repair and Carcinogenesis», Equipe Labellisée LIGUE 2016, CNRS UMR9019, Université Paris-Saclay, Gustave Roussy Cancer Campus, F-94805 Villejuif, France; [email protected] (A.A.I.); [email protected] (J.L.) * Correspondence: [email protected] (D.O.Z.); [email protected] (M.S.); Tel.: +7-(383)-3635187 (D.O.Z.); +33-(1)-42115404 (M.S.) Abstract: It was proposed that the last universal common ancestor (LUCA) evolved under high temperatures in an oxygen-free environment, similar to those found in deep-sea vents and on volcanic slopes. Therefore, spontaneous DNA decay, such as base loss and cytosine deamination, was the Citation: Prorok, P.; Grin, I.R.; major factor affecting LUCA’s genome integrity. Cosmic radiation due to Earth’s weak magnetic field Matkarimov, B.T.; Ishchenko, A.A.; and alkylating metabolic radicals added to these threats.
    [Show full text]
  • The Cubesat Mission to Study Solar Particles (Cusp) Walt Downing IEEE Life Senior Member Aerospace and Electronic Systems Society President (2020-2021)
    The CubeSat Mission to Study Solar Particles (CuSP) Walt Downing IEEE Life Senior Member Aerospace and Electronic Systems Society President (2020-2021) Acknowledgements – National Aeronautics and Space Administration (NASA) and CuSP Principal Investigator, Dr. Mihir Desai, Southwest Research Institute (SwRI) Feature Articles in SYSTEMS Magazine Three-part special series on Artemis I CubeSats - April 2019 (CuSP, IceCube, ArgoMoon, EQUULEUS/OMOTENASHI, & DSN) ▸ - September 2019 (CisLunar Explorers, OMOTENASHI & Iris Transponder) - March 2020 (BioSentinnel, Near-Earth Asteroid Scout, EQUULEUS, Lunar Flashlight, Lunar Polar Hydrogen Mapper, & Δ-Differential One-Way Range) Available in the AESS Resource Center https://resourcecenter.aess.ieee.org/ ▸Free for AESS members ▸ What are CubeSats? A class of small research spacecraft Built to standard dimensions (Units or “U”) ▸ - 1U = 10 cm x 10 cm x 11 cm (Roughly “cube-shaped”) ▸ - Modular: 1U, 2U, 3U, 6U or 12U in size - Weigh less than 1.33 kg per U NASA's CubeSats are dispensed from a deployer such as a Poly-Picosatellite Orbital Deployer (P-POD) ▸NASA’s CubeSat Launch initiative (CSLI) provides opportunities for small satellite payloads to fly on rockets ▸planned for upcoming launches. These CubeSats are flown as secondary payloads on previously planned missions. https://www.nasa.gov/directorates/heo/home/CubeSats_initiative What is CuSP? NASA Science Mission Directorate sponsored Heliospheric Science Mission selected in June 2015 to be launched on Artemis I. ▸ https://www.nasa.gov/feature/goddard/2016/heliophys ics-cubesat-to-launch-on-nasa-s-sls Support space weather research by determining proton radiation levels during solar energetic particle events and identifying suprathermal properties that could help ▸ predict geomagnetic storms.
    [Show full text]
  • Lunar Flashlight & NEA Scout
    National Aeronautics and Space Administration Lunar Flashlight & NEA Scout A NanoSat Architecture for Deep Space Exploration Payam Banazadeh (JPL/Caltech) Andreas Frick (JPL/Caltech) EM-1 Secondary Payload Selection • 19 NASA center-led concepts were evaluated and 3 were down-selected for further refinement by AES toward a Mission Concept Review (MCR) planned for August 2014 • Primary selection criteria: - Relevance to Space Exploration Strategic Knowledge Gaps (SKGs) - Life cycle cost - Synergistic use of previously demonstrated technologies - Optimal use of available civil servant workforce Payload Strategic Knowledge Gaps Mission Concept NASA Centers Addressed BioSentinel Human health/performance in high- Study radiation-induced DNA ARC/JSC radiation space environments damage of live organisms in cis- • Fundamental effects on biological systems lunar space; correlate with of ionizing radiation in space environments measurements on ISS and Earth Lunar Flashlight Lunar resource potential Locate ice deposits in the Moon’s JPL/MSFC/MHS • Quantity and distribution of water and other permanently shadowed craters volatiles in lunar cold traps Near Earth Asteroid (NEA) NEA Characterization Slow flyby/rendezvous and Scout • NEA size, rotation state (rate/pole position) characterize one NEA in a way MSFC/JPL How to work on and interact with NEA that is relevant to human surface exploration • NEA surface mechanical properties 2 EM-1: Near Earth Asteroid (NEA) Scout concept WHY NEA Scout? – Characterize a NEA with an imager to address key Strategic
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • Phenotype Microarrays Panels PM-M1 to PM-M14
    Phenotype MicroArrays™ Panels PM-M1 to PM-M14 for Phenotypic Characterization of Mammalian Cells Assays: Energy Metabolism Pathways Ion and Hormone Effects on Cells Sensitivity to Anti-Cancer Agents and for Optimizing Culture Conditions for Mammalian Cells PRODUCT DESCRIPTIONS AND INSTRUCTIONS FOR USE PM-M1 Cat. #13101 PM-M2 Cat. #13102 PM-M3 Cat. #13103 PM-M4 Cat. #13104 PM-M5 Cat. #13105 PM-M6 Cat. #13106 PM-M7 Cat. #13107 PM-M8 Cat. #13108 PM-M11 Cat. #13111 PM-M12 Cat. #13112 PM-M13 Cat. #13113 PM-M14 Cat. #13114 © 2016 Biolog, Inc. All rights reserved Printed in the United States of America 00P 134 Rev F February 2020 - 1 - CONTENTS I. Introduction ...................................................................................................... 2 a. Overview ................................................................................................... 2 b. Background ............................................................................................... 2 c. Uses ........................................................................................................... 2 d. Advantages ................................................................................................ 3 II. Product Description, PM-M1 to M4 ................................................................ 3 III. Protocols, PM-M1 to M4 ................................................................................. 7 a. Materials Required .................................................................................... 7 b. Determination
    [Show full text]
  • Chaotic Descriptor Table
    Castle Oldskull Supplement CDT1: Chaotic Descriptor Table These ideas would require a few hours’ the players back to the temple of the more development to become truly useful, serpent people, I decide that she has some but I like the direction that things are going backstory. She’s an old jester-bard so I’d probably run with it. Maybe I’d even treasure hunter who got to the island by redesign dungeon level 4 to feature some magical means. This is simply because old gnome vaults and some deep gnome she’s so far from land and trade routes that lore too. I might even tie the whole it’s hard to justify any other reason for her situation to the gnome caves of C. S. Lewis, to be marooned here. She was captured by or the Nome King from L. Frank Baum’s the serpent people, who treated her as Ozma of Oz. Who knows? chattel, but she barely escaped. She’s delirious, trying to keep herself fed while she struggles to remember the command Example #13: word for her magical carpet. Malamhin of the Smooth Brow has some NPC in the Wilderness magical treasures, including a carpet of flying, a sword, some protection from serpents thingies (scrolls, amulets?) and a The PCs land on a deadly magical island of few other cool things. Talking to the PCs the serpent people, which they were meant and seeing their map will slowly bring her to explore years ago and the GM promptly back to her senses … and she wants forgot about it.
    [Show full text]
  • Mechanism and Regulation of DNA Damage Recognition in Nucleotide Excision Repair
    Kusakabe et al. Genes and Environment (2019) 41:2 https://doi.org/10.1186/s41021-019-0119-6 REVIEW Open Access Mechanism and regulation of DNA damage recognition in nucleotide excision repair Masayuki Kusakabe1, Yuki Onishi1,2, Haruto Tada1,2, Fumika Kurihara1,2, Kanako Kusao1,3, Mari Furukawa1, Shigenori Iwai4, Masayuki Yokoi1,2,3, Wataru Sakai1,2,3 and Kaoru Sugasawa1,2,3* Abstract Nucleotide excision repair (NER) is a versatile DNA repair pathway, which can remove an extremely broad range of base lesions from the genome. In mammalian global genomic NER, the XPC protein complex initiates the repair reaction by recognizing sites of DNA damage, and this depends on detection of disrupted/destabilized base pairs within the DNA duplex. A model has been proposed that XPC first interacts with unpaired bases and then the XPD ATPase/helicase in concert with XPA verifies the presence of a relevant lesion by scanning a DNA strand in 5′-3′ direction. Such multi-step strategy for damage recognition would contribute to achieve both versatility and accuracy of the NER system at substantially high levels. In addition, recognition of ultraviolet light (UV)-induced DNA photolesions is facilitated by the UV-damaged DNA-binding protein complex (UV-DDB), which not only promotes recruitment of XPC to the damage sites, but also may contribute to remodeling of chromatin structures such that the DNA lesions gain access to XPC and the following repair proteins. Even in the absence of UV-DDB, however, certain types of histone modifications and/or chromatin remodeling could occur, which eventually enable XPC to find sites with DNA lesions.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Progress Report January 2009 – December 2011
    North Carolina State University Professional Science Master’s Program Progress Report January 2009 – December 2011 The Graduate School College of Agriculture & Life Sciences College of Design College of Education College of Engineering College of Humanities & Social Sciences Poole College of Management College of Natural Resources College of Physical & Mathematical Sciences College of Textiles College of Veterinary Medicine First-Year College 1 Greetings From the UNC System PSM Director The Professional Science Master’s (PSM) Program is one of the University of North Carolina (UNC) System’s ways to close the existing skills gap in the workplace. Together with local employers, we design graduate education and training regimens to match employers’ needs. The UNC System has undertaken a collaborative effort to develop these new programs in key areas of importance to North Carolina’s local economies. I am pleased to report that NC State University now offers nine PSM programs. Several new programs are at various planning stages, and numerous new central resources and services are available or under way for these programs. A special milestone in 2010 was the establishment of the PSM Council at NC State University. Members of this group include faculty who direct PSM programs or are planning to offer them in the future. The PSM Council oversees new program development and determines the future strategy for the PSM programs at NC State University. Another important milestone was the award of a new UNC System grant from the Alfred P. Sloan Foundation and support from the UNC General Administration for multiple online tools. I am greatly indebted to the many employers, professors and students who contribute to the collective success of NC State University’s PSM programs.
    [Show full text]